A Multiple-dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and QTc Effect of MK-8189 in Participants With Schizophrenia and Healthy Participants.
Phase of Trial: Phase I
Latest Information Update: 20 Dec 2018
At a glance
- Drugs MK 8189 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Acronyms MDCS
- Sponsors Merck Sharp & Dohme
- 11 Dec 2018 Planned End Date changed from 31 Dec 2018 to 9 Oct 2019.
- 11 Dec 2018 Planned primary completion date changed from 31 Dec 2018 to 9 Oct 2019.
- 11 Dec 2018 Status changed from recruiting to suspended pending evaluation of emerging preclinical findings